Search for: ""Daubert v. Merrell Dow Pharmaceuticals, Inc." OR "509 U.S. 579""
Results 81 - 100
of 112
Sort by Relevance
|
Sort by Date
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative"… [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
24 Aug 2010, 11:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in which the Court instructed district courts to function as gatekeepers and permit only reliable and relevant expert testimony to be presented to the jury. [read post]
4 Aug 2010, 7:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) established the test federal (and many state) judges currently use to determine the admissibility of expert testimony in trials and other proceedings. [read post]
8 Jul 2010, 3:30 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
23 Jun 2010, 3:35 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]
6 May 2010, 4:12 pm
Metabolife International, Inc., 401 F.3d 1233, 1247 (11th Cir. 2005); Goebel v. [read post]
31 Dec 2009, 2:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its federal and state progeny. [read post]
22 Dec 2009, 8:57 pm
Nutrinova, Inc., 579 F.3d 1363, 1374-76 (Fed. [read post]
18 Dec 2009, 11:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
15 Dec 2009, 1:56 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993)]). [read post]
25 Aug 2009, 7:53 am
Merrell Dow Pharmaceuticals, Inc. [read post]
22 May 2009, 8:53 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
13 Apr 2009, 1:01 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
27 Mar 2009, 7:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)). [read post]
23 Mar 2009, 7:28 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
9 Mar 2009, 7:31 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). [read post]
25 Feb 2009, 4:47 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
18 Feb 2009, 12:01 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 589 (1993) Can the Daubert requirement be fulfilled during the trial? [read post]
7 Feb 2009, 10:24 pm
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993); see also Weisgram v. [read post]
